The influence of sex, gestational age, birth weight, blood transfusion, and timing of the heel prick on the pancreatitis-associated protein concentration in newborn screening for cystic fibrosis

Journal of Inherited Metabolic Disease

Volumn 36, Issue 1, 2013, Pages 147-154

  Vernooij Van Langen, Annette M M ^a,b   Loeber, J Gerard ^b   Elvers, Bert ^b   Triepels, Ralf H ^c   Roefs, Jos ^c   Gille, Johan J ^d   Reijntjens, Sandra ^a   Dompeling, Edward ^e   Dankert Roelse, Jeannette E ^a  

^a Zuyderland Medical Centre   (Netherlands)

^b NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^c TweeSteden Hospital   (Netherlands)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PANCREATITIS ASSOCIATED PROTEIN;

ANALYTICAL PARAMETERS; ARTICLE; BIRTH WEIGHT; BLOOD SAMPLING; BLOOD TRANSFUSION; CYSTIC FIBROSIS; DISEASE MARKER; ELISA KIT; FALSE POSITIVE RESULT; FEMALE; GENDER; GESTATIONAL AGE; HUMAN; INFANT; LOW BIRTH WEIGHT; MAJOR CLINICAL STUDY; MALE; NETHERLANDS; NEWBORN; NEWBORN SCREENING; POPULATION RESEARCH; PREMATURITY; PRICK TEST; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; TIMING OF HEEL PRICK;

ANTIGENS, NEOPLASM; BIOLOGICAL MARKERS; BIRTH WEIGHT; BLOOD TRANSFUSION; CYSTIC FIBROSIS; FEMALE; GESTATIONAL AGE; HEEL; HUMANS; INFANT, NEWBORN; INFANT, PREMATURE; LECTINS, C-TYPE; MALE; NEONATAL SCREENING; SEX FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 84872618217     PISSN: 01418955     EISSN: 15732665     Source Type: Journal    
DOI: 10.1007/s10545-012-9498-6     Document Type: Article

References (20)

1. Castellani C, Southern KW et al. (2009) European best practice guidelines for cystic fibrosis neonatal screening. J Cyst Fibros 8(3):153-173
2. Closa D, Motoo Y et al. (2007) Pancreatitis-associated protein: from a lectin to an anti-inflammatory cytokine. World J Gastroenterol 13(2):170-174
3. De Boeck K, Wilschanski M et al. (2006) Cystic fibrosis: terminology and diagnostic algorithms. Thorax 61:627-635
4. Green A, Kirk J (2007) Guidelines for the performance of the sweat test for the diagnosis of cystic fibrosis. Ann Clin Biochem 44:25-34
5. Iovanna JL, Férec C et al. (1994a) The Pancreas-associated protein (PAP). A new candidate for neonatal screening of cystic fibrosis. C R Acad Sci Paris 317:561-564
6. Iovanna JL, Keim V et al. (1994b) Serum levels of pancreatitis-associated protein as indicators of the course of acute pancreatitis. Multicentric study group on acute pancreatitis. Gastroenterology 106(3):728-734
7. Kaye CI, Accurso F et al. (2006) Newborn screening fact sheets. Pediatrics 118(3):e934-e963
8. Keim V, Rohr G et al. (1984) An additional secretory protein in the rat pancreas. Digestion 29(4):242-249
9. Keim V, Willemer S et al. (1994) Rat pancreatitis-associated protein is expressed in relation to severity of experimental pancreatitis. Pancreas 9(5):606-612
10. LeGrys VA, Rosenstein BJ et al. (2000) Sweat testing: sample collection and quantative analysis; approved guideline-second edition. NCCLS 20(14)
11. Mayell SJ, Munck A et al. (2009) A European consensus for the evaluation and management of infants with an equivocal diagnosis following newborn screening for cystic fibrosis. J Cyst Fibros 8(1):71-78
12. Sarles J, Barthellemy S et al. (1999) Blood concentrations of pancreatitis assiciated protein in neonates: relevance to neonatal screening for cystic fibrosis. BMJ 80:118-122
13. Sarles J, Berthezene P et al. (2005) Combining immunoreactive trypsinogen and pancreatitis-associated protein assays, a method of newborn screening for cystic fibrosis that avoids DNA analysis. J Pediatr 147(3):302-305
14. Savkovic V, Gaiser S et al. (2004) The stress response of the exocrine pancreas. Dig Dis 22:239-246
15. Sommerburg O, Lindner M et al. (2010) Initial evaluation of a biochemical cystic fibrosis newborn screening by sequential analysis of immunoreactive trypsinogen and pancreatitis-associated protein (IRT/PAP) as a strategy that does not involve DNA testing in a northern European population. J Inherit Metab Dis 33(Suppl 2):S263-S271
16. Southern KW (2004) Newborn screening for cystic fibrosis: the practical implications. J R Soc Med 97(Suppl 44):57-59
17. van der Kamp HJ, Oudshoorn CG et al. (2005) Cutoff levels of 17-alpha-hydroxyprogesterone in neonatal screening for congenital adrenal hyperplasia should be based on gestational age rather than on birth weight. J Clin Endocrinol Metab 90(7):3904-3907
18. Vernooij-van Langen A, Loeber J, et al. (2012) Novel strategies in newborn screening for Cystic Fibrosis: a prospective controlled study. Thorax (in press)
19. Wilcken B (1987) An evaluation of screening for cystic fibrosis. Prog Clin Biol Res 254:201-215
20. Wilcken B (2007) Newborn screening for cystic fibrosis: Techniques and strategies. J Inherit Metab Dis